Sun Pharma to acquire Organon in an all-cash deal
Revenue nearly doubles; expands into women’s health and biosimilars
Signals shift to innovation-led global growth
In a defining move for India’s pharmaceutical sector, Sun Pharmaceutical Industries announced on Monday, April 27, the acquisition of US-listed Organon & Co. in an all-cash deal valued at $11.75 billion. Priced at $14 per share, the transaction is the largest-ever overseas acquisition by an Indian drugmaker and signals Sun Pharma’s intent to evolve into a more diversified, innovation-driven global player.
The deal significantly expands Sun Pharma’s footprint across high-value segments, including women’s health, biosimilars, and established branded medicines. Organon operates in over 140 countries and brings a strong portfolio spanning contraceptives, fertility treatments, and more than 50 established brands—along with a fast-growing biosimilars pipeline.
1 April 2026
Get the latest issue of Outlook Business
Shares of Sun Pharma rallied 6.76% on Monday after the announcement of the acquisition.
What Comes Next After the Deal
Post-acquisition, the combined entity is expected to generate annual revenues of about $12.4 billion, nearly doubling Sun Pharma’s current scale. EBITDA is projected at $3.7 billion, reflecting improved profitability and a more balanced business mix.
Importantly, the merger reduces reliance on commoditised generics by increasing exposure to branded and innovative therapies.
Sun Pharma plans to fund the deal through a mix of internal cash and committed bank financing. Despite the large outlay, leverage is expected to remain under control, supported by Organon’s robust cash flows, which exceed $1 billion annually. These funds will also help accelerate debt reduction after the acquisition.
Why It Matters Now
The acquisition comes as global pharma companies increasingly pivot toward specialty and innovation-led segments. For Sun Pharma, this is a timely opportunity to add a new growth pillar—women’s health—while strengthening its presence in advanced markets.
Management expects synergies exceeding $350 million within four years, driven by cost efficiencies, supply chain optimisation, and cross-market product expansion. The company also sees potential in leveraging Organon’s commercial network to scale new therapies globally.
With closing expected in early 2027, the combined business will have a strong presence across major markets and a workforce of around 24,000. The deal positions Sun Pharma as a more formidable global competitor, capable of driving sustained growth beyond traditional generics.
